Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
brinzolamide 1% · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Azopt 1% ophthalmic suspension | ACTIVE_COMPARATOR | Ophthalmic suspension |
| Brinzolamide 1% ophthalmic suspension | EXPERIMENTAL | ophthalmic suspension |
| Name | Type | Description |
|---|---|---|
| brinzolamide 1% ophthalmic suspension | DRUG | brinzolamide 1% ophthalmic suspension |
| Azopt 1% | DRUG | Azopt 1%, RLD |
Inclusion Criteria: * Male and females 18 years of age or older, * diagnosed with primary open-angle glaucoma or ocular hypertension. Exclusion Criteria: * Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Brinzolamide 1% is used for the treatment of glaucoma, specifically open-angle glaucoma or ocular hypertension. It is an ophthalmic solution developed by Bausch + Lomb Corporation. The drug is a small molecule administered as eye drops to help lower intraocular pressure in patients with these conditions.
Brinzolamide 1% is developed by Bausch + Lomb Corporation, a company listed on the stock exchange under the ticker BLCO. The company is conducting clinical trials to evaluate the therapeutic equivalence of generic brinzolamide compared to the reference product Azopt in patients with glaucoma.
Brinzolamide 1% is in Phase 3 clinical development for glaucoma. One completed Phase 3 trial (NCT01722604) evaluated its therapeutic equivalence to Azopt in 258 patients. Another completed Phase 1 trial (NCT03896633) enrolled 637 participants. The drug remains investigational and is not yet approved.
Brinzolamide 1% has two completed clinical trials. NCT01722604 is a Phase 3 study with 258 participants, and NCT03896633 is a Phase 1 study with 637 participants. Both trials assessed therapeutic equivalence of generic brinzolamide versus Azopt in patients with open-angle glaucoma or ocular hypertension in the United States.
Brinzolamide 1% works by inhibiting the enzyme carbonic anhydrase, which reduces the production of aqueous humor in the eye, thereby lowering intraocular pressure. This mechanism helps manage glaucoma and ocular hypertension by decreasing fluid buildup that can damage the optic nerve.
Brinzolamide 1% is being studied as a generic version of Azopt. Clinical trials are designed to demonstrate therapeutic equivalence between the generic brinzolamide formulation and Azopt, the reference product. Both contain the same active ingredient, brinzolamide, at a 1% concentration.